1,726 results on '"Cohen, Stanley"'
Search Results
2. Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
3. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
4. Janus kinase inhibitors: efficacy and safety
5. Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
6. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
7. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
8. Oral surveillance and JAK inhibitor safety: the theory of relativity
9. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
10. Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination
11. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
12. Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
13. A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
14. Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease.
15. A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn's Disease Improves Outcomes at 2 Years.
16. Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results.
17. Increasing Prevalence and Racial Disparity of Alcohol-Related Gastrointestinal and Liver Disease During the COVID-19 Pandemic: A Population-Based National Study
18. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
19. Dealing with Multi-Dimensional Data and the Burden of Annotation: Easing the Burden of Annotation
20. A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
21. Clinical Characteristics, Hospitalization, and Mortality Rates of Coronavirus Disease 2019 Among Liver Transplant Patients in the United States: A Multicenter Research Network Study
22. False Flag Over Ramapo: a Novella in Legal Pleadings.
23. Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
24. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection
25. Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis
26. Drug-Induced Liver Injury from Statins
27. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
28. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial
29. A Treat to Target Strategy Using Panenteric Capsule Endoscopy in Pediatric Patients With Crohn’s Disease
30. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
31. Epidemiology of Autoimmune Hepatitis (AIH) in the United States Between 2014 and 2019: A Population-based National Study
32. A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
33. What Advice Current Pathology Chairs Seek From Former Chairs
34. A Comparison of Osteopathic, Pharmacy, Physical Therapy, Physician Assistant and Occupational Therapy Students' Personality Styles: Implications for Education and Practice.
35. A standardized scoring system for conflict of interest determination and mitigation for AASLD-sponsored continuing medical education events.
36. Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial
37. Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosis
38. The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn’s Disease in Children
39. Effects of Threshold Choice on Biological Conclusions Reached during Analysis of Gene Expression by DNA Microarrays
40. JAK inhibitors and VTE risk: how concerned should we be?
41. EST-Based Genome-Wide Gene Inactivation Identifies ARAP3 as a Host Protein Affecting Cellular Susceptibility to Anthrax Toxin
42. Reverse Transcriptase Activity Innate to DNA Polymerase I and DNA Topoisomerase I Proteins of Streptomyces Telomere Complex
43. Asynchronous Replication Timing of Telomeres at Opposite Arms of Mammalian Chromosomes
44. Catalytic Activation of Multimeric RNase E and RNase G by 5′-Monophosphorylated RNA
45. Global Analysis of Escherichia coli RNA Degradosome Function Using DNA Microarrays
46. PKHD1 Protein Encoded by the Gene for Autosomal Recessive Polycystic Kidney Disease Associates with Basal Bodies and Primary Cilia in Renal Epithelial Cells
47. TSG101 Interaction with HRS Mediates Endosomal Trafficking and Receptor Down-Regulation
48. Senescence-Specific Gene Expression Fingerprints Reveal Cell-Type-Dependent Physical Clustering of Up-Regulated Chromosomal Loci
49. The Catalytic Domain of RNase E Shows Inherent 3′ to 5′ Directionality in Cleavage Site Selection
50. Global Analysis of mRNA Decay and Abundance in Escherichia coli at Single-Gene Resolution Using Two-Color Fluorescent DNA Microarrays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.